Symbiotec Pharmalab makes tepid market debut, lists at par with IPO price
The listing of Symbiotec Pharmalab was well below GMP expectations, which had indicated a listing gain of around 18-19 per cent for IPO investors.
5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.business-standard.com — the content belongs to Business Standard.
